Anaconda Biomed has announced that it has named long-time medtech executive Trent Reutiman as its new chief executive officer (CEO).
A press release details that, based in California’s San Francisco Bay Area, Reutiman will establish a “new footprint” for the company in the USA as it works towards regulatory approval of its ANA5 advanced neurovascular access—a catheter-based technology designed to improve neurovascular interventions by enhancing the capabilities of existing and forthcoming intravascular devices.
Reutiman brings more than 25 years of executive, financial, market development and sales operation leadership experience to Anaconda Biomed, with an extensive focus in vascular technologies. Prior to his new position, he was the CEO of Mercator MedSystems, where he oversaw the development of the company’s catheter-based drug delivery system for treating peripheral arterial disease (PAD) and other venous vascular conditions, raised consecutive rounds of capital, and negotiated a financing and strategic partnership with Shenzhen Salubris Pharmaceuticals.
Previously, he was vice president of global commercial operations for IDEV—a company solving unmet revascularisation needs in PAD—which was acquired by Abbott in 2013. Reutiman has also served in leadership roles at ROX Medical, OmniSonics Medical Technologies, and RITA Medical Systems. He holds a bachelor’s degree in business and economics from Colorado State University (Fort Collins, USA) and a Master of Business Administration degree from the University of California (Irvine, USA).
Reutiman replaces previous Anaconda Biomed CEO Francois Salmon, who will now serve as the company’s board chairman.
“With its ANA funnel catheter technology, Anaconda Biomed has the potential to deliver a meaningful improvement in first-pass reperfusion outcomes, the latest standard in mechanical thrombectomy procedures for ischaemic stroke,” Reutiman said. “The company’s ATHENA study is designed to demonstrate clinically meaningful changes for ischaemic stroke patients through arrested flow and more secure clot retrieval. I am honoured to join the company to build on its successes to date and look forward to working closely with Francois, the board, the talented Anaconda team, and all of our study partners, to bring this new technology to clinicians and patients in the USA and worldwide.”
“Trent is joining Anaconda at a pivotal time as we advance our clinical programme and build evidence supporting FDA [Food and Drug Administration] approval of the ANA funnel catheter in the USA,” Salmon added. “On behalf of myself and the rest of the board, we welcome his leadership and contributions moving forward.”
